Mylan GmbH
12
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
67%
8 trials in Phase 3/4
50%
6 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers
Role: collaborator
MYL-1401A Efficacy and Safety Comparability Study to Humira®
Role: collaborator
Adalimumab PK Bioequivalence Study to EU and US Sourced Humira
Role: collaborator
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
Role: collaborator
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
Role: collaborator
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
Role: collaborator
Mylan Insulin Glargine Study
Role: collaborator
Mylan Insulin Aspart Study
Role: collaborator
Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta
Role: collaborator
Efficacy and Safety Study With MYL-1401H and Neulasta
Role: collaborator
Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.
Role: collaborator
Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion
Role: collaborator
All 12 trials loaded